{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-029207","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2024-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.359544+00:00","generated_at":"2026-06-04T23:46:33.451612+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CytomX FY2023 revenue $101.2M, operating expenses down 30%; BMS discontinues 986288, CX-904 data H2 2024","bullets":["FY2023 revenue $101.2M (up from $53.2M in 2022); operating expenses $107.7M (down from $154.5M).","Cash $174.5M at Dec 31, 2023 vs $193.7M a year earlier; includes $30M from July 2023 BVF financing.","BMS notified CytomX it will not continue BMS-986288 beyond current Phase 2; research collaboration with multiple TCE programs continues.","CX-904 EGFRxCD3 Phase 1a data expected H2 2024; CX-2051 and CX-801 Phase 1 starts H1 2024 after IND clearance."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-029207","json":"https://secwatch.observer/filing/0000950170-24-029207.json","markdown":"https://secwatch.observer/filing/0000950170-24-029207.md","text":"https://secwatch.observer/filing/0000950170-24-029207.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000095017024029207/0000950170-24-029207-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000095017024029207/ctmx-20240311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:46:33.451612+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e3093bed8e172b3b4877fbf42ce262de7ee1c944","claim":"CytomX Therapeutics, Inc. reported financial results for the year ended December 31, 2023.","evidence_excerpt":"On March 11, 2024, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000095017024029207/0000950170-24-029207-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}